MIR761 (MicroRNA 761)

MiR-761 is a critical regulator of PDCD4, modulating laryngeal cancer progression through apoptosis inhibition and pro-metastatic signaling. Targeting the miR-761/PDCD4 axis offers a promising therapeutic strategy for laryngeal cancer management.

In addition, the miR-761 inhibitor reversed the inhibitory effect of si-CASC19 on the biological activity of ovarian cancer cells, while si-CBX2 restored the regulation of miR-761 inhibitor on the development of ovarian cancer. lncRNA CASC19 mediated the malignant progression of ovarian cancer through miR-761/CBX2 axis, which provided a potential therapeutic target for the cure of patients.

Mechanistically, dual-luciferase reporter and RIP assays demonstrated that circ_0008389 served as a miRNA molecular sponge specifically binding to miR-761, thereby stabilizing the P2RY2 transcript and inhibiting RNA degradation pathways, which maintains pro-tumor signaling. This study established circ_0008389 as a key driver of ESCC progression and metastasis, providing new insights for the treatment of ESCC.

Mechanistically, METTL3 inhibited the FENDRR/TFRC axis to alleviate DDP-induced ferroptosis, promoting DDP resistance in LUAD cells. Collectively, our findings identify a novel molecular regulatory mechanism in DDP resistance of LUAD, and suggest that FENDRR might be an attractive target for addressing DDP resistance.

FOXM1 mediated the transcription of PCNA and influenced the p21 degradation, which resulted in up-regulation of p21 protein in a p53-independent manner. In conclusion, our findings showed that N6-methyladenosine modification by METTL3 and YTHDF1 stabilized circRPS6KC1, and circRPS6KC1 played an essential role on cellular senescence via FOXM1/PCNA axis in prostate cancer.

Circ_0038718 aggravated the progression of CRC cells via mediating ITGA6 expression through targeting miR-761 and miR-214-3p, providing a new therapeutic target for CRC patients.

This article reviews the current understanding of the biological function and clinical significance of LOXL1-AS1 in human cancers. These findings suggest that LOXL1-AS1 may be both a reliable biomarker and a potential therapeutic target for cancers.

Among these enriched genes, only TPM2, SRPX and SRGAP1 were significantly negatively correlated with miR-424-5p and were positively linked to hsa_circ_0000375 in CRC without or with liver metastasis. Collectively, the current findings elucidated a potential hsa_circ_0000375-miR-424-5p-TPM2/SRPX/SRGAP1 network contributing to liver metastasis of CRC.

Upregulation of miR-761 or downregulation of DACT2 partially reversed the biological process of TNBC and the prognosis of paclitaxel affected by circDUSP1. Taken together, our findings revealed a role for the regulation of the miR-761/DACT2 axis by circDUSP1 in the biological process of TNBC. These results provided new insights into the biological mechanism and targeted therapy of TNBC.